Independent

Weight loss drugs linked to loss of hair in major new study

Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation

The Telegraph

Fat Jabs Increase Risk Of Hair Loss By Up To 70Pc

Daily Mail

Lose your hair AND your belly: Using fat jabs make you 68 per cent more likely to go bald, study suggests

newstart_2024

drgabriellelyon

Science Media Centre

expert reaction to a target trial emulation study on risk of hair loss associated with GLP-1 RAs in adults with type 2 diabetes

glennhealth

People

GLP-1 Medications Linked to Increased Hair Loss in New Study — Here’s How Much They Raise the Risk of Alopecia

News Medical

GLP-1 receptor agonists may increase hair loss risk

Reuters

Hair loss with GLP-1 drugs is rare, but real, studies find

MedPage Today

New Study Links GLP-1s to Hair Loss

Sky News

Weight loss drugs linked to increased risk of hair loss, researchers say

RTE.ie

Weight loss drugs 'linked to hair loss' - study

ScienceAlert

Study Finds a Worrying New Side Effect of GLP-1 Drugs That No One's Talking About

Medicalxpress

GLP-1 diabetes drugs linked to up to 68% higher hair loss risk

Metaculus

Oral Semaglutide Approval by 2027

A study published in The BMJ on Wednesday found that GLP-1 receptor agonist drugs — including semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro) — were associated with a 37% higher risk of alopecia than SGLT-2 inhibitors and a 68% higher risk than DPP-4 inhibitors.

A study published in The BMJ on Wednesday found that GLP-1 receptor agonist drugs — including semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro) — were associated with a 37% higher risk of alopecia than SGLT-2 inhibitors and a 68% higher risk than DPP-4 inhibitors.

The study, led by researchers at the University of Pennsylvania, used electronic health records from January 2019 to September 2024, comparing 12,004 GLP-1 drug users with 15,221 SGLT-2 inhibitor users and 11,964 GLP-1 users with 11,233 DPP-4 inhibitor users.

The study, led by researchers at the University of Pennsylvania, used electronic health records from January 2019 to September 2024, comparing 12,004 GLP-1 drug users with 15,221 SGLT-2 inhibitor users and 11,964 GLP-1 users with 11,233 DPP-4 inhibitor users.

The elevated hair loss risk was specific to non-scarring alopecia, in which hair follicles remain intact and regrowth is possible, as GLP-1 users showed a 53% and 72% higher risk than SGLT-2 and DPP-4 inhibitor users, respectively.

The elevated hair loss risk was specific to non-scarring alopecia, in which hair follicles remain intact and regrowth is possible, as GLP-1 users showed a 53% and 72% higher risk than SGLT-2 and DPP-4 inhibitor users, respectively.

Researchers said the most likely mechanism behind hair loss in GLP-1 users relates to weight loss and reduced caloric intake, which may cause micronutrient deficiencies — such as iron, zinc and biotin — that disrupt the hair growth cycle.

Researchers said the most likely mechanism behind hair loss in GLP-1 users relates to weight loss and reduced caloric intake, which may cause micronutrient deficiencies — such as iron, zinc and biotin — that disrupt the hair growth cycle.

The absolute rate of alopecia among GLP-1 users was low, ranging from roughly 3 to 9 per 1,000 people per year. Researchers noted the findings may still influence patients' decisions to start or continue therapy.

The absolute rate of alopecia among GLP-1 users was low, ranging from roughly 3 to 9 per 1,000 people per year. Researchers noted the findings may still influence patients' decisions to start or continue therapy.

The U.K.'s Medicines and Healthcare products Regulatory Agency had received 399 reports of hair loss linked to tirzepatide in 2026 so far, alongside 541 in the prior year, and 148 reports tied to semaglutide, alongside 164 the year before.

The U.K.'s Medicines and Healthcare products Regulatory Agency had received 399 reports of hair loss linked to tirzepatide in 2026 so far, alongside 541 in the prior year, and 148 reports tied to semaglutide, alongside 164 the year before.

Independent #

BMJ #

The Telegraph #

Daily Mail #

Science Media Centre #

People #

News Medical #

Reuters #

MedPage Today #

Sky News #

RTE.ie #

ScienceAlert #

Medicalxpress #

Metaculus #

A study published in The BMJ found that GLP-1 receptor agonist drugs — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — were associated with a 37% higher risk of alopecia than SGLT-2 inhibitors and a 68% higher risk than DPP-4 inhibitors.

A study published in The BMJ found that GLP-1 receptor agonist drugs — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — were associated with a 37% higher risk of alopecia than SGLT-2 inhibitors and a 68% higher risk than DPP-4 inhibitors.

The elevated hair loss risk was specific to non-scarring alopecia, where hair follicles remain intact and regrowth is possible, with GLP-1 users showing a 53% and 72% higher risk compared with SGLT-2 and DPP-4 inhibitor users, respectively.

The elevated hair loss risk was specific to non-scarring alopecia, where hair follicles remain intact and regrowth is possible, with GLP-1 users showing a 53% and 72% higher risk compared with SGLT-2 and DPP-4 inhibitor users, respectively.

The UK's Medicines and Healthcare products Regulatory Agency had received 399 reports of hair loss linked to tirzepatide in 2026 so far, alongside 541 in the prior year, and 148 reports tied to semaglutide, alongside 164 the year before.

The UK's Medicines and Healthcare products Regulatory Agency had received 399 reports of hair loss linked to tirzepatide in 2026 so far, alongside 541 in the prior year, and 148 reports tied to semaglutide, alongside 164 the year before.

GLP-1 drugs like Ozempic carry a 37% higher hair loss risk, but that's no reason to panic — the shedding is temporary and nonscarring, with hair typically regrowing once weight stabilizes. The absolute risk stays low at roughly 6.91 cases per 1,000 person-years, meaning only two to three extra cases compared to alternative diabetes meds. The metabolic benefits of better glycemic control and reduced obesity-related complications far outweigh this manageable side effect.

GLP-1 drugs like Ozempic carry a 37% higher hair loss risk, but that's no reason to panic — the shedding is temporary and nonscarring, with hair typically regrowing once weight stabilizes. The absolute risk stays low at roughly 6.91 cases per 1,000 person-years, meaning only two to three extra cases compared to alternative diabetes meds. The metabolic benefits of better glycemic control and reduced obesity-related complications far outweigh this manageable side effect.

Glenn Ellis, MPH

Hair loss from GLP-1 drugs is just one piece of a much uglier picture — rapid fat loss also destroys facial volume, accelerates visible aging and causes muscle wasting that no one is warning patients about upfront. Hairdressers and plastic surgeons are already seeing the fallout firsthand, and poor healing adds another serious concern. These are powerful medications with real consequences, especially for people using them for modest weight loss goals.

Hair loss from GLP-1 drugs is just one piece of a much uglier picture — rapid fat loss also destroys facial volume, accelerates visible aging and causes muscle wasting that no one is warning patients about upfront. Hairdressers and plastic surgeons are already seeing the fallout firsthand, and poor healing adds another serious concern. These are powerful medications with real consequences, especially for people using them for modest weight loss goals.

Camus

Dr. Gabrielle Lyon

Weight loss drugs linked to loss of hair in major new study

Ozempic Linked to 37% Higher Hair Loss Risk

Health

Obesity

Diseases & conditions

Pharmaceuticals

This study provides valuable evidence that weight-loss drugs increase the risk of non-scarring hair loss. However, hair loss from GLP-1 drugs is just one piece of a much uglier picture — rapid fat loss also destroys facial volume, accelerates visible aging and causes muscle wasting that no one is warning patients about upfront. These are powerful medications with real consequences, especially for people using them for modest weight loss goals.

This study provides valuable evidence that weight-loss drugs increase the risk of non-scarring hair loss. However, hair loss from GLP-1 drugs is just one piece of a much uglier picture — rapid fat loss also destroys facial volume, accelerates visible aging and causes muscle wasting that no one is warning patients about upfront. These are powerful medications with real consequences, especially for people using them for modest weight loss goals.

Although methodologically robust, this observational study cannot establish causation, leaving residual confounding and alternative explanations unresolved. While GLP-1 receptor agonists were linked to a higher relative risk of non-scarring hair loss, the absolute increase was small — only two to three additional cases per 1,000 person-years. The findings warrant awareness but should not overshadow the therapies' proven metabolic and cardiovascular benefits.

Although methodologically robust, this observational study cannot establish causation, leaving residual confounding and alternative explanations unresolved. While GLP-1 receptor agonists were linked to a higher relative risk of non-scarring hair loss, the absolute increase was small — only two to three additional cases per 1,000 person-years. The findings warrant awareness but should not overshadow the therapies' proven metabolic and cardiovascular benefits.

There's an 80% chance that oral semaglutide will be approved by the FDA or EMA for the treatment of obesity by 2027, according to the Metaculus prediction community.

There's an 80% chance that oral semaglutide will be approved by the FDA or EMA for the treatment of obesity by 2027, according to the Metaculus prediction community.

Study Links Weight Loss Drugs to 37% Higher Hair Loss Risk

OzempicStudy LinkedLinks Weight Loss Drugs to 37% Higher Hair Loss Risk

The Spin

Metaculus Prediction

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Study Links Weight Loss Drugs to 37% Higher Hair Loss Risk

OzempicStudy LinkedLinks Weight Loss Drugs to 37% Higher Hair Loss Risk

The Spin

Metaculus Prediction

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters